Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate
(b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of
acute bacterial rhinosinusitis.